Please assess the completion status of the following clinical trial:

Trial Title: Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Patients must either be:~   * treatment-naïve with newly diagnosed her2neu non-overexpressing (non amplified) metastatic (Stage IV) breast cancer, or~  * HER2/neu-negative patients with metastasis diagnosed 6 or more months after completing primary systemic treatment (neoadjuvant, adjuvant chemotherapy).~2. No previous chemotherapy regimen for metastatic breast cancer.~3. 18 years of age or older.~4. Measurable disease as defined by RECIST criteria or evaluable disease.~5. Eastern Cooperative Oncology Group (ECOG) 0-1.~6. Life expectancy greater than 3 months.~7. For female (or male) patients, either pre- or post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control for the duration of the study~8. Provide written informed consent before any study-related procedure not part of normal medical care is conducted~9. Willing and able to comply with the protocol requirement~10. Laboratory parameters as follows:~    * Neutrophils: 1.5 x109/L or greater~   * Platelets: 100 x109/L or greater~   * Hemoglobin: ≥ 9.0 g/dL~   * Serum Creatinine: ≤ 1.5mg/dL~   * Bilirubin: ≤ ULN, except when caused by metastatic disease~   * Alanine transaminase (ALT)/Aspartate transaminase (AST): ≤ 2.5 times the upper limit of the normal range (ULN) except when caused by metastatic disease~   * Urine protein creatinine (UPC) ratio \< 1.0 at screening.~Exclusion Criteria~1. Previous treatment with gemcitabine.~2. History of Gastrointestinal Bleeding in the previous 3 months.~3. Chemotherapy within 4 weeks prior to enrollment.~4. Radiation therapy or evidence of acute effects of radiation therapy within 2 weeks prior to enrollment.~5. Any major surgery within 4 weeks prior to enrollment.~6. Presence of central nervous system or brain metastases.~7. Urine protein: creatinine ratio ≥ 1.0 at screening.~8. Inadequately controlled hypertension (defined as systolic blood pressure \> 150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications).~9. A prior history of hypertensive crisis or hypertensive encephalopathy.~10. Peripheral neuropathy \> grade I.~11. Clinical AIDS or known positive HIV serology~12. No concurrent clinically evident malignancy is allowed except inactive non-melanoma skin cancer and inactive cervical cancer diagnosed or other cancer for which the patient has been disease-free for five years.~13. Unstable angina.~14. New York Heart Association (NYHA) Grade II or greater congestive heart failure~15. History of myocardial infarction within 6 months.~16. History of stroke within 6 months.~17. Clinically significant peripheral vascular disease.~18. Evidence of bleeding diathesis or coagulopathy~19. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, anticipation of need for major surgical procedure during the course of the study.~20. Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to enrollment.~21. Pregnant (positive pregnancy test) or lactating.~22. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to enrollment~23. Serious, non-healing wound, ulcer, or bone fracture~24. Inability to comply with study and/or follow-up procedures~25. Participants with serious medical or psychiatric illness that would render chemotherapy unsafe are ineligible.~26. Participants cannot have been in another experimental drug study other than a Bevacizumab cancer study within 4 weeks of the first infusion of these study medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Abraxane, Avastin and Gemcitabine (Type: EXPERIMENTAL): Each treatment cycle is 28 days. Participants will be treated until disease progression:~* Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~* Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~* Avastin: 10 mg/kg IV on days 1 and 15 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).